Cardiff Oncology to Release Q1 Financial Results and Provide Update on Lead Asset, Onvansertib

On May 2, at 4:30 p.m. ET/1:30 p.m. PT in San Diego, Cardiff Oncology, Inc., a clinical-stage biotechnology company focused on developing novel therapies using PLK1 inhibition for various types of cancers, will be holding a conference call and webcast to release their financial results for the first quarter ended March 31, 2024.

Individuals interested in listening to the call can do so using the webcast link in the “Investors” section of Cardiff Oncology’s website. A replay of the call will be available in the investor relations section of the website after the call is completed.

Cardiff Oncology’s lead asset is onvansertib, a PLK1 inhibitor currently undergoing evaluation in combination with standard-of-care therapeutics for various indications such as RAS-mutated metastatic colorectal cancer and metastatic pancreatic ductal adenocarcinoma. The company’s development strategy is designed to target tumor vulnerabilities to overcome treatment resistance and deliver better clinical outcomes. More information can be found on Cardiff Oncology’s website.

For further information about this announcement or to schedule an interview with a member of the Cardiff Oncology team, please contact Kiki Patel, PharmD at Gilmartin Group or Grace Spencer at Taft Communications.